Targeting the Epithelial Alarmin Pathway with Tezepelumab in Highly Comorbid, Biologic-Experienced Severe Asthma: 52-Week Real-World Outcomes.

Although reduction in maintenance OCS dose did not reach statistical significance at 26 weeks, a significant decrease was observed at one year, likely reflecting cautious tapering in patients with long-standing steroid dependence and multimorbidity [ 18 , 35 , 41 , 42 ].

also in 111,027 other papers